

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT OF THE COMPANY

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with information on the latest product development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 13 December 2017, the China Food and Drug Administration (the “**CFDA**”) has announced on its website that our certification applications for Ankura II Stent Graft System and SeQure™ Snare System have been approved.

Ankura II stent graft system contains the stent graft and the delivery system, in which the stent graft, a tube composed of ePTFE film supported by a metal mesh called a stent, is loaded inside the delivery system. The system is an upgraded version of our existing product Ankura stent graft, with significant performance enhancements. Ankura II stent graft system obtained this CFDA certificate for endovascular repair on patients with thoracic dissection. When the stent graft is deployed after being delivered to the lesion sites by delivery system, the self-expanding stent graft isolates the flow of blood from the lesion sites and allows blood to pass through without pressure on the lesion sites, achieving good treatment effects. Our Ankura II stent graft system has previously obtained CE marking in 2011 and was launched successfully in the European market.

The SeQure™ Snare System consists of snare, catheter, snare loader and torque. It is intended for use to snare and retrieve foreign objects such as fractured catheters or guidewire within the cardiovascular system. The product has previously obtained US FDA registration and CE marking in 2010, and was launched successfully in the European market.

The Company believes the CFDA certification and subsequent launch of Ankura II Stent Graft System and SeQure™ Snare System in China will further assist the Company to expand its market share, enhance competitiveness and market position with global coverage, thereby strongly promoting the steady development of the Group.

Going forward, the Company reaffirms its commitment in independent innovation and development, in pursuit of benefitting patients globally through its minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Executive Director, Chairman
and Chief Executive Officer*

Hong Kong, 15 December 2017

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Mr. ZHANG Deyuan being executive Directors; Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.